4,952 Shares in Globus Medical Inc (GMED) Acquired by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC purchased a new position in shares of Globus Medical Inc (NYSE:GMED) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 4,952 shares of the medical device company’s stock, valued at approximately $204,000.

Other hedge funds also recently made changes to their positions in the company. Aperio Group LLC raised its holdings in Globus Medical by 11.3% during the fourth quarter. Aperio Group LLC now owns 42,788 shares of the medical device company’s stock worth $1,759,000 after purchasing an additional 4,356 shares during the last quarter. Pembroke Management LTD acquired a new position in Globus Medical during the fourth quarter worth $9,720,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Globus Medical by 39.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,183 shares of the medical device company’s stock worth $172,000 after purchasing an additional 1,183 shares during the last quarter. Mutual of America Capital Management LLC raised its holdings in Globus Medical by 3.8% during the fourth quarter. Mutual of America Capital Management LLC now owns 58,892 shares of the medical device company’s stock worth $2,420,000 after purchasing an additional 2,134 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Globus Medical by 9.0% during the fourth quarter. Jennison Associates LLC now owns 23,038 shares of the medical device company’s stock worth $947,000 after purchasing an additional 1,900 shares during the last quarter. Institutional investors own 69.67% of the company’s stock.

Shares of Globus Medical Inc (NYSE:GMED) traded up $0.85 on Wednesday, reaching $46.13. The company had a trading volume of 347,660 shares, compared to its average volume of 675,553. The stock has a market capitalization of $4,360.00, a P/E ratio of 41.77, a P/E/G ratio of 2.64 and a beta of 0.48. Globus Medical Inc has a 1 year low of $26.86 and a 1 year high of $47.09.

GMED has been the subject of a number of analyst reports. BTIG Research set a $42.00 price target on Globus Medical and gave the stock a “buy” rating in a report on Monday, November 20th. Gabelli reiterated a “buy” rating on shares of Globus Medical in a research note on Tuesday, November 14th. BidaskClub upgraded Globus Medical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. ValuEngine upgraded Globus Medical from a “hold” rating to a “buy” rating in a research note on Friday, November 10th. Finally, Canaccord Genuity reissued a “buy” rating and set a $38.00 price target on shares of Globus Medical in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $40.57.

In related news, CAO Steven Payne sold 3,076 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $39.30, for a total value of $120,886.80. Following the completion of the transaction, the chief accounting officer now directly owns 23,847 shares of the company’s stock, valued at approximately $937,187.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David D. Davidar sold 55,383 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $40.66, for a total value of $2,251,872.78. Following the completion of the transaction, the director now directly owns 752,236 shares of the company’s stock, valued at $30,585,915.76. The disclosure for this sale can be found here. Insiders have sold 73,459 shares of company stock worth $2,947,260 in the last 90 days. 28.21% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “4,952 Shares in Globus Medical Inc (GMED) Acquired by Greenwood Capital Associates LLC” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/14/greenwood-capital-associates-llc-buys-new-stake-in-globus-medical-inc-gmed.html.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply